{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:19:55Z","timestamp":1794856795281,"version":"4.9.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["634413"],"award-info":[{"award-number":["634413"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["777377"],"award-info":[{"award-number":["777377"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Metab"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Non-alcoholic fatty liver disease (NAFLD) is a common, progressive liver disease strongly associated with the metabolic syndrome. It is unclear how progression of NAFLD towards cirrhosis translates into systematic changes in circulating proteins. Here, we provide a detailed proteo-transcriptomic map of steatohepatitis and fibrosis during progressive NAFLD. In this multicentre proteomic study, we characterize 4,730 circulating proteins in 306 patients with histologically characterized NAFLD and integrate this with transcriptomic analysis in paired liver tissue. We identify circulating proteomic signatures for active steatohepatitis and advanced fibrosis, and correlate these with hepatic transcriptomics to develop a proteo-transcriptomic signature of 31 markers. Deconvolution of this signature by single-cell RNA sequencing reveals the hepatic cell types likely to contribute to proteomic changes with disease progression. As an exemplar of use as a non-invasive diagnostic, logistic regression establishes a composite model comprising four proteins (ADAMTSL2, AKR1B10, CFHR4 and TREM2), body mass index and type 2 diabetes mellitus status, to identify at-risk steatohepatitis.<\/jats:p>","DOI":"10.1038\/s42255-023-00775-1","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T12:03:06Z","timestamp":1681128186000},"page":"572-578","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":188,"title":["A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4426-6930","authenticated-orcid":false,"given":"Olivier","family":"Govaere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0325-4298","authenticated-orcid":false,"given":"Megan","family":"Hasoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6831-9806","authenticated-orcid":false,"given":"Simon","family":"Cockell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Tiniakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Ekstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-4703","authenticated-orcid":false,"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Boursier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6865-3791","authenticated-orcid":false,"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"LITMUS Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann K.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9518-0088","authenticated-orcid":false,"given":"Quentin M.","family":"Anstee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"775_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","volume":"16","author":"QM Anstee","year":"2019","unstructured":"Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O. & Heikenwalder, M. From NASH to HCC: current concepts and future challenges. Nat. Rev. Gastroenterol. Hepatol. 16, 411\u2013428 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"775_CR2","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/jclinpath-2013-201620","volume":"66","author":"JK Dyson","year":"2013","unstructured":"Dyson, J. K., McPherson, S. & Anstee, Q. M. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J. Clin. Pathol. 66, 1033\u20131045 (2013).","journal-title":"J. Clin. Pathol."},{"key":"775_CR3","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"},{"key":"775_CR4","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.jhep.2021.05.008","volume":"75","author":"R Younes","year":"2021","unstructured":"Younes, R. et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J. Hepatol. 75, 786\u2013794 (2021).","journal-title":"J. Hepatol."},{"key":"775_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jhepr.2019.06.004","volume":"1","author":"M Boyle","year":"2019","unstructured":"Boyle, M. et al. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Rep. 1, 188\u2013198 (2019).","journal-title":"JHEP Rep."},{"key":"775_CR6","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1002\/hep.31995","volume":"74","author":"K Kozumi","year":"2021","unstructured":"Kozumi, K. et al. Transcriptomics identify thrombospondin-2 as a biomarker for NASH and advanced liver fibrosis. Hepatology 74, 2452\u20132466 (2021).","journal-title":"Hepatology"},{"key":"775_CR7","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","volume":"5","author":"PN Newsome","year":"2020","unstructured":"Newsome, P. N. et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol. Hepatol. 5, 362\u2013373 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"775_CR8","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/hep4.1670","volume":"5","author":"Y Luo","year":"2021","unstructured":"Luo, Y. et al. SOMAscan proteomics identifies serum biomarkers associated with liver fibrosis in patients with NASH. Hepatol. Commun. 5, 760\u2013773 (2021).","journal-title":"Hepatol. Commun."},{"key":"775_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2021.09.026","volume":"76","author":"KE Corey","year":"2022","unstructured":"Corey, K. E. et al. ADAMTSL2 protein and a soluble biomarker signature identify significant and advanced fibrosis in adults with NAFLD. J. Hepatol. 76, 25\u201333 (2022).","journal-title":"J. Hepatol."},{"key":"775_CR10","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41591-022-01850-y","volume":"28","author":"L Niu","year":"2022","unstructured":"Niu, L. et al. Noninvasive proteomic biomarkers for alcohol-related liver disease. Nat. Med. 28, 1277\u20131287 (2022).","journal-title":"Nat. Med."},{"key":"775_CR11","doi-asserted-by":"crossref","unstructured":"Veyel, D. et al. Biomarker discovery for chronic liver diseases by multi-omics \u2013 a preclinical case study. Sci. Rep. 10, 1314 (2020).","DOI":"10.1038\/s41598-020-58030-6"},{"key":"775_CR12","doi-asserted-by":"publisher","first-page":"106175","DOI":"10.1016\/j.cct.2020.106175","volume":"98","author":"T Hardy","year":"2020","unstructured":"Hardy, T. et al. The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemp. Clin. Trials 98, 106175 (2020).","journal-title":"Contemp. Clin. Trials"},{"key":"775_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06318-7","volume":"9","author":"SA MacParland","year":"2018","unstructured":"MacParland, S. A. et al. Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nat. Commun. 9, 4383 (2018).","journal-title":"Nat. Commun."},{"key":"775_CR14","doi-asserted-by":"publisher","first-page":"eaba4448","DOI":"10.1126\/scitranslmed.aba4448","volume":"12","author":"O Govaere","year":"2020","unstructured":"Govaere, O. et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci. Transl. Med. 12, eaba4448 (2020).","journal-title":"Sci. Transl. Med."},{"key":"775_CR15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","volume":"575","author":"P Ramachandran","year":"2019","unstructured":"Ramachandran, P. et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature 575, 512\u2013518 (2019).","journal-title":"Nature"},{"key":"775_CR16","doi-asserted-by":"crossref","unstructured":"Dobie, R. et al. Single-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis. Cell Rep. 29, 1832\u20131847.e8 (2019).","DOI":"10.1016\/j.celrep.2019.10.024"},{"key":"775_CR17","doi-asserted-by":"crossref","unstructured":"Indira Chandran, V. et al. Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness. Hepatology 77, 558\u2013572 (2023).","DOI":"10.1002\/hep.32620"},{"key":"775_CR18","doi-asserted-by":"crossref","unstructured":"Hendrikx, T. et al. Soluble TREM2 levels reflect the recruitment and expansion of TREM2(+) macrophages that localize to fibrotic areas and limit NASH. J. Hepatol. 77, 1373\u20131385 (2022).","DOI":"10.1016\/j.jhep.2022.06.004"},{"key":"775_CR19","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1038\/s41591-019-0665-2","volume":"25","author":"SA Williams","year":"2019","unstructured":"Williams, S. A. et al. Plasma protein patterns as comprehensive indicators of health. Nat. Med. 25, 1851\u20131857 (2019).","journal-title":"Nat. Med."},{"key":"775_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44\u201357 (2009).","journal-title":"Nat. Protoc."}],"container-title":["Nature Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42255-023-00775-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-023-00775-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-023-00775-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T11:02:43Z","timestamp":1682506963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42255-023-00775-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["775"],"URL":"https:\/\/doi.org\/10.1038\/s42255-023-00775-1","relation":{},"ISSN":["2522-5812"],"issn-type":[{"value":"2522-5812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,10]]},"assertion":[{"value":"15 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.G. reports grants from NanoString Technologies. L.A. is employed by SomaLogic, Inc. D.T. reports consultation fees from Histoindex Pte Ltd. M.E. is a member of the advisory board at AMRA Medical AB. J.M.S. reports consultancy for Apollo Endosurgery, Albireo Pharma Inc, Bayer, BMS, Boehringer Ingelheim, Echosens, Genfit, Gilead Sciences, GSK, Heel GmbH, Intercept Pharmaceuticals, Ipsen, Inventiva Pharma, Julius Clinical, Madrigal, MSD, Nordic Bioscience, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Shinogi, Siemens Healthcare GmbH and Summit Clinical Research; research funding from Gilead Sciences, Boehringer Ingelheim, Nordic Bioscience and Siemens Healthcare GmbH; and speaker honoraria from MedPublico GmbH and Boehringer Ingelheim, all outside of the submitted work. J.B. consults for and received grants from Echosens and Siemens. E.B. served as a consultant or advisory board member for Boehringer Ingelheim, Gilead Sciences, Intercept, Inventiva, Merck, Novo Nordisk, Pfizer, ProSciento and a speaker for Gilead Sciences, MSD and Novo Nordisk, outside of the submitted work. Q.M.A. reports grants from European Commission during the conduct of the study; other grants from AstraZeneca, Boehringer Ingelheim, Intercept; consultancy for Alimentiv, Akero, AstraZeneca, Axcella, 89Bio, Boehringer Ingelheim, Bristol Myers Squibb, Galmed, Genfit, Genentech, Gilead, GlaxoSmithKline, Hanmi, HistoIndex, Intercept, Inventiva, Ionis, IQVIA, Janssen, Madrigal, Medpace, Merck, NGMBio, Novartis, Novo Nordisk, PathAI, Pfizer, Prosciento, Poxel, Resolution Therapeutics, Roche, Ridgeline Therapeutics, RTI, Shionogi, Terns. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}